Age-dependent parathormone levels and different CKD-MBD treatment practices of dialysis patients in Hungary - Results from a nationwide clinical audit

BMC Nephrology

Volumn 14, Issue 1, 2013, Pages

  Kiss, István ^a,b   Kiss, Zoltán ^c   Ambrus, Csaba ^b   Szabó, András ^a   Szegedi, János ^d   Balla, József ^e   Ladányi, Erzsébet ^f   Csiky, Botond ^f   Árkossy, Ottó ^f   Török, Marietta ^g   Túri, Sándor ^h   Kulcsár, Imre ⁱ  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b Szent Imre Hospital   (Hungary)

^c School for PhD Candidates of Aesculap Academy   (Hungary)

^d Plant and Soil Protection Directorate   (Hungary)

^e UNIVERSITY OF DEBRECEN   (Hungary)

^f Fresenius Medical Care   (Hungary)

^g Diaverum Hungary Ltd   (Hungary)

^h UNIVERSITY OF SZEGED   (Hungary)

ⁱ Markusovszky Teaching Hospital   (Hungary)

Author keywords

Calcium (Ca); Chronic kidney disease (CKD); Chronic kidney disease mineral and bone disorder (CKD MBD); End stage renal disease (ESRD); Parathyroid hormone (PTH); Phosphate (PO ssub 4 esub )

Indexed keywords

CALCIMIMETIC AGENT; PARATHYROID HORMONE; PHOSPHATE; PHOSPHATE BINDING AGENT; VITAMIN D DERIVATIVE;

ADULT; AGED; ARTICLE; BONE DISEASE; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; FEMALE; GROUPS BY AGE; HEMODIALYSIS; HORMONE BLOOD LEVEL; HUMAN; HUNGARY; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MEDICAL AUDIT; MEDICAL RECORD REVIEW; PERITONEAL DIALYSIS; RETROSPECTIVE STUDY;

AGE FACTORS; AGED; BIOLOGICAL MARKERS; BONE DENSITY; CLINICAL AUDIT; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HUNGARY; MALE; MIDDLE AGED; PARATHYROID HORMONE; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84880182223     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-14-155     Document Type: Article

References (30)

1. Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: improving global outcomes (KDIGO). Moe S, Drüeke T, Cunningham J, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G, Kidney Int 2006 69 1945 1953
2. The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism. Rodriguez M, Nemeth E, Martin D, Am J Physiol Renal Physiol 2005 288 253 F264
3. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Floege J, Kim J, Ireland E, Chazot C, Drueke T, de Francisco A, Kronenberg F, Marcelli D, Passlick-Deetjen J, Schernthaner G, Fouqueray B, Wheeler DC, ARO Investigators, Nephrol Dial Transplant 2011 26 1948 1955
4. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kalantar-Zadeh K, Kuwae N, Regidor DL, Kovesdy CP, Kilpatrick RD, Shinaberger CS, McAllister CJ, Budoff MJ, Salusky IB, Kopple JD, Kidney Int 2006 70 771 780
5. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease. A systematic review and meta-analysis. Palmer SC, Hayen A, Macaskill P, Pellegrini F, Craig JC, Elder GJ, Strippoli GF, JAMA 2011 305 11 1119 1127
6. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the dialysis outcomes and practice patterns study (DOPPS). Young EW, Akiba T, Albert J, McCarthy JT, Kerr PG, Mendelssohn DC, Jadoul M, Am J Kidney Dis 2004 44 5 Suppl 2 34 38
7. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. Goodman WG, Goldin J, Kuizon B, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB, N Engl J Med 2000 342 1478 1483
8. Effects excess PTH on nonclassical target organs. Bro S, Olgaard K, Am J Kidney Dis 1997 30 606 620
9. Examination and treatment of renal osteodystrophy (ROD). Szabó A, Mucsi I, Túri S, Kiss I, Poór G, Hypertonia és Nephrologia 2007 11 5 217 232 in Hungarian
10. Clinical guide to bone and mineral metabolism in CKD. Olgard K, National Kidney Foundation 2006
11. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003 42 4 Suppl 3 1 201
12. Evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). KDIGO Clinical Practice Guideline for the Diagnosis, Kidney Int 2009 76 Suppl 113 1 130
13. Szabó A, Deák G, Kiss I, Ladányi E, Mucsi I, Tislér A, Török M, Mátyus J, Reusz G, Haris Á Nagy J, Szegedi J, Examination and treatment of CKD-MBD. Textbook of guidelines of Nephrology Medition Publishing Ltd 2011 1 25 in Hungarian
14. Guidelines and clinical practice: clinical audit of CKD-MBD in Hungarian dialyzed patients. Kiss I, Kiss Z, Szabó A, Szegedi J, Balla J, Ladányi E, Csiky B, Árkossy O, Török M, Túri S, Kulcsár I, Hypertonia és Nephrologia 2012 16 1 23 30 in Hungarian
15. Renal replacement therapy in the elderly population. Berger JR, Hedayati S, Clin J Am Soc Nephrol 2012 7 1039 1046
16. Focused clinical campaign improves mineral and bone disorder outcomes. Benner D, Nissenson AR, Van Wyck D, J Ren Care 2011 [Epub ahead of print] 10.1111/j.1755-6686.2011.00233.x
17. Improving CKD-MBD management in haemodialysis patients: barrier analysis for implementing better practice. Toussaint ND, Pedagogos E, Beavis J, Becker GJ, Polkinghorne KR, Kerr PG, Nephrol Dial Transplant 2011 26 1319 1326
18. Chronic kidney disease-mineral and bone disorder (CKD-MBD) management and associated cost in an Irish haemodyalisis cohort. Ward F, Watson A, Holian J, Nephrol Dial Transplant 2011 26 10 3417
19. Mineral and bone disease pattern in elderly haemodialysis patients. Pelletier S, Roth H, Boucher JL, Drueke T, London G, Fouque D, the French Phosphorus and Calcium Observatory investigators, Nephrol Dial Transplant 2010 25 3062 3070
20. Adynamic bone disease: pathogenesis, diagnosis and clinical relevance. Mucsi I, Hercz G, Curr Opin Nephrol Hypertens 1997 6 4 356 361
21. Risk factors for renal osteodystrophy: a multivariant analysis. Pei Y, Hercz G, Greenwood C, Segre G, Manuel A, Saiphoo C, Fenton S, Sherrard D, J Bone Miner Res 1995 10 1 149 156
22. Effects of high concentrations of glucose on PTH secretion in parathyroid cells. Sugimoto T, Ritter C, Morrissey J, Hayes C, Slatopolsky E, Kidney Int 1990 37 1522 1527
23. Renal osteodystrophy in diabetic patients. Pei Y, Hercz G, Greenwood C, Segre G, Manuel A, Saiphoo C, Fenton S, Sherrard D, Kidney Int 1993 44 1 159 164
24. Is there a lesser hyperparathyroidism in diabetic patients with chronic renal failure? Martinez I, Saracho R, Moina I, Montenegro J, Llach F, Nephrol Dial Transplant 1998 13 suppl 3 9 11
25. COSMOS: the dialysis scenario of CKD-MBD in Europe. Fernández- Martín JL, Carrero JJ, Benedik M, Bos WJ, Covic A, Ferreira A, Floege J, Goldsmith D, Gorriz JL, Ketteler M, Kramar R, Locatelli F, London G, Martin PY, Memmos D, Nagy J, Naves-Díaz M, Pavlovic D, Rodríguez- García M, Rutkowski B, Teplan V, Tielemans C, Verbeelen D, Wüthrich RP, Martínez-Camblor P, Cabezas-Rodriguez I, Sánchez-Alvarez JE, Cannata-Andia JB, Nephrol Dial Transplant 2012 0 1 11 10.1093/ndt/gfs418
26. Mineral metabolism management in haemodialysis patients with secondary hyperparathyroidism in Japan: Baseline data from the MBD-5D. Fukagawa M, Komaba H, Onishi Y, Fukuhara S, Akizawa T, Kurokawa K, MBD-5D Study Group, Am J Nephrol 2011 33 427 437
27. Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the dialysis outcomes and practice patterns study (DOPPS) DOOPS. Goodkin DA, Bragg-Gresham JL, Koenig KG, Wolfe RA, Akiba T, Andreucci VE, Saito A, Rayner HC, Kurokawa K, Port FK, Held PJ, Young EW, J Am Soc Nephrol 2003 10 3270 3277
28. Current management of secondary hyperparathyroidism: multicenter observational study (COSMOS). Cannata-Andía JB, Fernández- Martín JL, Zoccali C, London GM, Locatelli F, Ketteler M, Ferreira A, Covic A, Floege J, Górriz JL, Rutkowski B, Memmos DE, Verbeelen D, Tielemans C, Teplan V, Bos WJ, Nagy J, Kramar R, Goldsmith DJ, Martin PY, Wüthrich RP, Pavlovic D, Benedik M, J Nephrol 2008 21 290 298
29. The pathophysiology of secondary hyperparathyroidism and the consequencies of uncontrolled mineral metabolism in chronic kidney disease: the role of COSMOS. Cannata-Andía JB, Carrera F, Nephrol Dial Transplant Plus 2008 1 Suppl 1 2 6
30. Achievements in CKD-MBD guidelines targets: is there a progress in the implementation practice? Spasovski G, Zdravkovska V, Zabzun M, Antarorov R, Ivanovski K, Janakievska P, Neskovski J, Karceva-Sarajlia E, Panova B, Petrovska T, Zulbeari L, Masin-Spasovska J, Taleska-Matovska N, Gelev S, Int Urol Nephrol 2012 44 6 1791 828